400 SPECTRUM CENTER DRIVE, IRVINE, CA
Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026 Annual Meeting Results; Directors Elected at CG Oncology, Inc.
CG Oncology, Inc. Announces Separation of President Ambaw Bellete
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Appointment of Jim DeTore as Chief Financial Officer
Reports 2025 Year End Financial Results and Provides Business Updates
CG Oncology, Inc. Files Amendment No. 1 for $550 Million Common Stock Offering
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Amended Registration Statement for Securities
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report